Xtant Medical Boosts 2026 Outlook Amid Tough Quarter

Xtant Medical Holdings Inc ((XTNT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Xtant Medical Holdings Inc.’s latest earnings call struck a cautiously optimistic tone, blending significant strategic wins with stark near‑term challenges. Management highlighted strengthened liquidity, debt reduction, and new growth platforms, yet investors were reminded that revenue, margins, and earnings all deteriorated sharply in the first quarter.

Raised 2026 Revenue Outlook Despite Soft Q1

Xtant raised its full‑year 2026 revenue guidance to a range of $101 million to $105 million, signaling confidence that its new portfolio and sales investments will restore growth. Management tied the higher outlook to recent product introductions and sales‑force expansion, even as current‑year comparisons remain difficult.

HEMOBLAST Deal Opens Large Hemostatic Market

The company announced an exclusive U.S. distribution agreement for HEMOBLAST Bellows with Dilon Technologies, giving Xtant access to an estimated $2 billion global hemostatic market. The collagen‑ and thrombin‑based product adds a differentiated hemostat to the portfolio and is expected to generate immediate cross‑sell opportunities.

Sales-Force Expansion via Dilon Team Acquisition

As part of the HEMOBLAST agreement, Xtant hired Dilon’s team of 21 sales professionals, significantly broadening its commercial footprint. Management believes this expanded sales force will accelerate adoption of both HEMOBLAST and Xtant’s existing biologics, supporting the company’s long‑term growth ambitions.

Companion Spine Sale Fortifies Balance Sheet

Xtant received the final $10.7 million payment from the Companion Spine divestiture, bringing total proceeds to $21.4 million. These funds were used to reduce borrowings, cutting total indebtedness by $13.3 million in the first quarter and improving the company’s financial flexibility.

Trivium Shaped Launch Extends Allograft Platform

The commercial rollout of Trivium Shaped introduced pre‑shaped allograft forms such as boats and strips designed to improve handling in the operating room. Early surgeon feedback has been positive, and management views the product as both a clinical enhancement and a meaningful commercial growth driver within its spine portfolio.

Lean Cost Structure After Companion Spine Exit

Operating expenses declined to $14.9 million in the first quarter from $19.2 million a year earlier, largely reflecting the impact of the Companion Spine divestitures. General and administrative costs and sales and marketing both moved lower, while research and development spending was essentially flat, producing a leaner baseline expense profile.

Revolver Availability and Liquidity Improve

Availability under Xtant’s revolving credit facility climbed to $11.8 million at quarter‑end from $3.8 million at year‑end, driven by lower outstanding borrowings. Management emphasized that this expanded access to capital, along with reduced interest expense, strengthens overall liquidity despite a declining cash balance.

Revenue Drops Sharply on Amnio and Q-Code Pressure

Total revenue fell to $20.9 million from $32.9 million on a pro forma basis, a drop of about 36.5 percent year over year. Management pointed to reimbursement changes impacting amnio products and the end of certain license and Q‑code revenues as key drivers of the downturn.

Margin Compression Follows Mix Shift

Gross margin slid to 57.3 percent from 61.5 percent, reflecting the loss of high‑margin Q‑code license revenue and some adverse product mix. Executives expect margins to recover back toward the low‑60 percent range in the second half as new products scale and mix normalizes.

From Profit to Loss as EBITDA Turns Negative

The company reported a net loss of $3.1 million, or $0.02 per share, compared with a small profit in the prior‑year period. Adjusted EBITDA also weakened meaningfully, swinging to a $1.6 million loss from roughly $3.0 million of positive adjusted EBITDA a year earlier.

Cash Down as Debt Levels Come Down Too

Cash and cash equivalents fell to $12.2 million from $17.3 million at year‑end, a decline of about 29.5 percent. Management noted that a portion of available cash and Companion Spine proceeds was deliberately deployed to pay down debt, leaving the company with equal amounts of cash and total debt.

Short-Term Expense Headwinds From Commercial Build-Out

Integrating the Dilon team and doubling regional sales reps will drive sales and marketing expense higher over the near term. Management cited incremental quarterly sales and marketing costs in the several‑million‑dollar range, which will pressure margins before the added capacity begins to deliver meaningful revenue.

Amnio and OEM Volatility Clouds Near-Term Outlook

Amnio revenue remains under pressure due to reimbursement changes and softness in the advanced wound care market, while OEM stem‑cell sales were characterized as lumpy and soft. These headwinds create ongoing volatility in certain product lines, complicating the company’s path back to steady top‑line growth.

Guidance Signals Confidence in Second-Half Rebound

Management’s updated outlook calls for 2026 revenue of $101 million to $105 million, underpinned by the HEMOBLAST distribution deal, Trivium Shaped launch, and a larger commercial organization. Executives also expect gross margins to rebound into the low‑60 percent range later in the year as debt reduction and expanded revolver availability support continued investment.

Xtant’s earnings call painted a picture of a business in transition, trading near‑term revenue and profit softness for strategic positioning and balance‑sheet strength. Investors will now watch whether the expanded sales force and new products can overcome amnio and OEM headwinds and turn today’s cautious optimism into sustainable growth and margin recovery.